Keppra (levetiracetam) is a widely prescribed seizure medication that works well for most people who take it. In clinical trials, roughly 45% of patients experienced at least a 50% reduction in seizure frequency, compared to about 20% on placebo. Its effectiveness varies depending on the type of epilepsy, the patient’s age, and whether it’s used alone or alongside other medications.
Responder Rates in Clinical Trials
The standard measure of whether a seizure medication “works” is the responder rate: the percentage of people whose seizure frequency drops by half or more. In a double-blind, placebo-controlled trial of Keppra for partial seizures, 44.6% of patients on the drug hit that threshold, versus 19.6% on placebo. About 7% of patients on Keppra became completely seizure-free during the treatment period, compared to just 1% on placebo.
These numbers come from add-on therapy trials, where Keppra was given to people whose seizures weren’t fully controlled by another medication. When used as the sole treatment, seizure-free rates tend to be higher because the drug is typically started earlier in the course of the condition, when epilepsy is often more responsive to treatment.
Focal vs. Generalized Epilepsy
Keppra’s effectiveness depends significantly on the type of epilepsy being treated. For focal epilepsy (seizures starting in one area of the brain), about 19.7% of patients achieved seizure freedom on Keppra as a single medication over an average follow-up of about 18 months. For generalized epilepsy (seizures involving both sides of the brain from the start), that number nearly doubled to 39.5% over a similar period.
This pattern holds across most seizure medications. Generalized epilepsy tends to respond better to treatment overall, with about 41% of patients becoming seizure-free on monotherapy compared to roughly 22% of those with focal epilepsy. Keppra’s performance falls in line with other first-line options for both seizure types.
How Keppra Compares to Other Medications
A systematic review of 10 randomized controlled trials involving over 4,400 patients compared Keppra directly to carbamazepine, one of the oldest and most established seizure medications. Seven of those studies found the two drugs comparable in both seizure-free rates and side effects. Three studies actually favored Keppra, finding better seizure control and fewer adverse reactions. Overall, the evidence shows Keppra performs on par with carbamazepine at both 6 and 12 months.
In children, a meta-analysis of 14 studies covering nearly 900 pediatric patients compared Keppra to oxcarbazepine (another common option). The two medications showed no meaningful difference in seizure-free rates, responder rates, or overall side effect profiles. One advantage Keppra did show: it had less impact on thyroid function and bone health in children, which matters for a medication that may be taken throughout childhood and adolescence.
Effectiveness in Emergency Seizures
Keppra is also used intravenously in hospitals to treat status epilepticus, a dangerous condition where seizures don’t stop on their own. A large trial published in The Lancet tested Keppra against two other IV medications and found all three performed similarly. Keppra stopped the prolonged seizure in 52% of children, 44% of adults, and 37% of older adults. The other medications produced nearly identical results, making Keppra one of three equally viable options in this emergency setting.
How Quickly It Starts Working
Keppra reaches effective blood levels relatively fast compared to many seizure medications. Clinical trials show a beneficial effect during the initial dose-increase period, which typically spans the first few weeks of treatment. The standard approach is to start at a lower dose and increase every two weeks until reaching the target. Most people are at their full dose within four to six weeks, though some notice fewer seizures even during the early ramp-up phase.
This relatively quick onset is one reason Keppra is often chosen as a first-line treatment. Some older seizure medications require slower increases over months before reaching therapeutic levels.
What Affects How Well It Works for You
Several factors influence whether Keppra will be effective in any individual case. Seizure type matters most: generalized tonic-clonic seizures respond roughly twice as well as focal seizures. Age plays a role too, with children generally responding better than older adults in both routine and emergency use.
Whether Keppra is your first medication also matters. People trying their first seizure medication have significantly better odds of becoming seizure-free than those who have already tried and failed other treatments. If a previous medication didn’t work because of side effects rather than lack of seizure control, Keppra may still be a strong option since it tends to be well tolerated.
For focal seizures that don’t respond well to Keppra alone, adding it to another medication can make a meaningful difference. The 45% responder rate in add-on trials represents people who were already on at least one other drug without adequate control, so that additional benefit is genuinely on top of what they were already getting.